Reports half-year FY23 results:
Revenue of $370m vs. $393m expected
EBITDA of $189m vs. $190m expected
Net profit of $150m, down 4%: Beat analyst expectations of $129m
Cash and cash equivalents of $934.2m, up 38.5%
“These results were achieved despite significant production challenges due to water supply issues in the first quarter and the start of the second quarter as well as rapid increases in costs, particularly for chemical inputs.” - CEO Amanda Lacaze
Reports half-year FY23 results:
Revenue of $864.1m, down -34.2%
Base pathology revenue up 1% compared to prior corresponding period
PCR testing demand dropped nearly $500m from 1H22 highs
Net loss of $28.7m compared to $233.2m profit a year ago
“Taking into consideration its short-term gearing levels and cash conservation, the Board has determined not to pay an interim dividend for 1H 2023.”
Outlook:
“After an extraordinary trading period, lowering our cost curve has been key at Healius. We will continue to drive efficiencies as we introduce greater levels of automation into every aspect of our business. However, at these volumes we are comfortable that this largely fixed cost base can absorb a substantial increase and we expect to deliver margin expansion from revenue growth.” - CEO Maxine Jaquet
Reports full-year 2022:
Revenue of US$16.8bn, up 142%
Net profit of $6.5bn, up 228%
Underlying net profit of US$5.23bn below US$5.56bn expected
Final dividend of US$1.44 per share (ex-dividend March 9th)
FY23 Outlook:
Production guidance of 180-190MMboe
Capital expenditures of US$6.0-6.5bn
Woodside’s gas hub exposure guidance for the portfolio, as a % of produced LNG, is 20 – 25%
Reports 1HFY23:
EBITDA of $298.3m vs. $210.3m in 1HFY22 (+42%)
NPAT of $135.3m VS. $84.7M (+72%)
Final dividend of 8.8cps
Free cash flow of $214.7m
Revaluation of contracts key driver behind strong NPAT result
Customer growth climbed 2.2% in 1HFY23 (+10.2K)
Outlook:
FY23 EBITDA upgraded to $515m from $500m
“Subject to hydrological conditions, gas availability, and unforeseeable circumstances”
FY23 capex expected to be $80m
Reports 1HFY23:
Revenue of $363.4m vs. $327.1m YoY (+11%)
NPAT of $37.6m vs. $37.1m YoY
Comparable EBIT of $54.5m vs. $51.6m YoY (+6%)
Interim dividend of 4cps vs. 3.5cps YoY
MHJ bought back 2.2% of share capital in 1HFY23 @ 8.6m shares
Outlook:
Flat EBIT expected YoY (FY22 comparable EBIT was $62.9m)
Year to Date (YTD) sales in line with management forecasts
Reports 1HFY23:
Adjusted EBIT of -$4.4m
Adjusted NPAT -$9.6m vs. $4.8m YoY
Gross sales of $471.1m
Active Kogan customers at 3.32m
Excess inventory down -38% in 1HFY23
No dividend
Outlook:
Kogan declined to pay dividend cautious that positive January data may not hold up
Company expects to return to adjusted EBITDA profitability in second half
Gross sales expected to hit $68.8m (+33% YoY)
Operating costs expected to fall by -22.1% YoY
Reports 1HFY23:
NPAT of $-27.2m vs. $12.3m YoY
Sales revenue of $168.6m -8% YoY but in line with consensus
Underlying EBITDA of -$17.8m vs. $27.6m YoY Sales down -17% YoY but improved from November and December trends
No dividend
Outlook:
Logistics enhancement strategy “on track”
Stores have improved materially in ANZ and US
Company to pivot away from larger-than-normal clearance sales to whittle down inventory
“On track for positive net cash positon at FY end”
Get the latest news and insights direct to your inbox